TNF-α inhibitors, mainly including Etanercept, Infliximab, Adalimumab, Certolizumab, and Golimumab, are the earliest approved monoclonal antibodies for relieving psoriasis symptoms. The gene discussed is TNF; the disease is psoriasis.